Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Shanghai Fosun Pharmaceutical Industrial Development Co: Clinical Trials & FDA Approval Profile

Shanghai Fosun Pharmaceutical Industrial Development Co (Global / Institutional) sponsors 17 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 14 active protocols (4 recruiting now), 1 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)167 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Shanghai Fosun Pharmaceutical Industrial Development Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)17
Active Pipeline (Recruiting Now)14 (4)
Completed vs Stopped Early1 / 0 (0.0%)
Median Closed Actual Enrollment167 participants
Physical Hospital Site Disclosure94.5% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Shanghai Fosun Pharmaceutical Industrial Development Co
Hospital Research SiteLocationShared Protocols
Peking University First HospitalBeijing, Beijing Municipality3
West China Hospital,Sichuan UniversityChengdu, Sichuan2
The Fourth Hospital of Hebei Medical UniversityShijiazhuang, Hebei2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05997602To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCHPhase IIRECRUITING
NCT05913037FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform NeurofibromasPhase IIIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Shanghai Fosun Pharmaceutical Industrial Development Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI